Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by robertshawon Jul 12, 2019 4:08pm
69 Views
Post# 29915219

RE:RE:Dr. Jewett ...

RE:RE:Dr. Jewett ...
Bunge wrote:
Claridge wrote: It's been exactly 2 weeks since Dr Jewett mentioned in his AGM video (@12h37 ... "we have a patient pending and by the time this video is aired we may have actually enrolled as the 1st patient on this Ph. 2 study").

The Ph. 2b clinical trial record mentions this:

Screening Period

Patients will be qualified for Study entry by review of inclusion and exclusion criteria during the Screening Period, which will last up to 28 days
 

Follow-Up Phase

All patients enrolled and treated by the treatment procedure will be followed until the End of Study defined as completion of all required assessments after 12 months of follow-up post treatment or earlier due to early discontinuation or withdrawal of informed consent.


Dr. Jewett wouldn't have played game here, as later on in the video, he goes full disclosure about the "jocking" of patients (@17:15+ ... "I've spoken to the canadian on-boarding happening this year with enrollment and the rate of enrollment is somewhat uncertain because this is a crowed space currently, full disclosure, there are other trials being conducted and we're working with these sites to take on this trial or they've already agreed to take on, knowing that there's going to be some "jocking" between patients for different trial eligibility but we're confident based on the track record of these sites, KOL, lead sites with a lot of close ties with us Theralase and that they will meet their recrutment rates .....")


So the recruitment process is in motion.  That we know that.  For the rest, just like in any other trial, the rate of enrollment cannot be predicted, for those unfamiliar with such process.  Only rough estimates can be given as rough guidances.  

Who knows if we won't have a news release a bit before July 22 stating that x patients had been recruited and treated (instead of just the 1st one) that will spike the share price!


benny, got your sweetheart shares and warrants locked in yet before anyone else knows the terms?



Just wish all of the enrolled patients long time ago good luck, don't die all before the scheduled (supposed to be December 2018, and changed to January 2019, then early Q2, then only God knows which days..), but the long suffered shareholders have no obligation to pay the funeral fees for those patients and have no obligation to pay for pimp (prostitute) management's nasty hobby of unnecessary dirty low levels dilution with shameless agencies.
Bullboard Posts